SymBiosis Capital Management, LLC (“SymBiosis”) and HealthTech Arkansas today announced the creation of BioAR Trial, an accelerator program created to help biotherapeutics companies in late pre-clinical stages of development and bring ground-breaking therapies to market more quickly while enhancing Arkansans’ access to advanced clinical care and advanced medications.
SymBiosis and HealthTech Arkansas are in a fantastic position to advance the objectives of the BioAR Trial as a team. A Bentonville-based business called SymBiosis has a lot of financial resources, experience guiding several biotherapeutics businesses through different growth stages, and excellent operational and scientific competencies.
HealthTech Arkansas has contacts with the largest hospitals and health systems in the state that it will use to deliver high-quality clinical trial sites in Arkansas that can promptly enroll a variety of populations to BioAR Trial participating organizations.
Companies from all over the world are invited to apply to participate in the BioAR Trial, which will focus on using cutting-edge therapeutic modalities to treat serious and life-threatening diseases in oncology, immune disorders, and cardio-metabolic disease. These modalities include genetic medicines, cell therapies, biologics, and precision medicines.
“Our objective at SymBiosis is to create investments that assist bring breakthrough therapeutics to market to enhance and preserve lives,” says Chidozie Ugwumba, Managing Partner of SymBiosis.
According to Jeff Stinson, Director of HealthTech Arkansas, “working with SymBiosis to construct BioAR Trial is a crucial next step towards completing our mission to stimulate innovation for Arkansas healthcare providers through our accelerators and internal innovation programming.” The ability of our healthcare accelerator to provide top-notch clinical trial settings for potential early-stage entrepreneurs will be combined with SymBiosis’ extensive experience in aiding biotherapeutic companies to carry out their vital missions.
According to Jahan Ali, Vice President of Business Development at SymBiosis, who will be in charge of the BioAR Trial, “We take very seriously the task of helping to accelerate the growth and success of companies developing some of the most promising therapeutics in the world by streamlining the clinical trial process.” “SymBiosis and’s combined resources and expertise include:
